CYCN: Cyclerion Price/Earnings to Growth Multiple

Corporate company logo of Cyclerion (CYCN)

Operational structural transformations are already priced in, which is why the PEG ratio dynamics show no immediate growth. The current level of 0.00 reflects the P/E to growth ratio, helping to identify the asset's undervaluation. Cyclerion Therapeutics (CYCN) business potential relies on the advancement of pralinocaine and sGC patents, while the diversification of research for rare vascular pathologies minimizes the company's scientific risks.

Cyclerion Therapeutics - CYCN PEG Multiple (period 07/04/2022 - 09/09/2026)

Analytical breakdowns for Cyclerion (CYCN)

Fundamental company analysis:CYCN - Cyclerion Therapeutics
Finished products of Cyclerion Therapeutics Inc.

To minimize long-term risks, investors should evaluate the cost of growth by comparing the P/E ratio with earnings dynamics. Since Cyclerion Therapeutics (CYCN) lacks pricing power and depends on future licensing payments, the ratio of the company's valuation to its growth rate helps determine whether the market is overpaying for the potential of a research entity whose fundamental stability remains hypothetical.

Competitors of Cyclerion Therapeutics

Growth-Adjusted Market Cap to Net Income Biogen Idec|Neurocrine Corp - Price/Earnings to Growth Multiple|regencellbioscience.com (RGC) - Price to Earnings Adjusted for Growth Rate|AXSM - Price/Earnings to Growth Ratio|ACAD (ACADIA Pharmaceuticals Inc.) - Growth-Adjusted P/E Ratio|Xenon Pharmaceuticals (XENE) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio VKTX|Price/Earnings to Growth Ratio Supernus|Price to Earnings Adjusted for Growth Rate catalystpharma.com CPRX|Price/Earnings to Growth Multiple DNLI (Denali Therapeutics Inc.)|HRMY - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Biohaven Ltd. BHVN|AMLX (Amylyx) - Market Cap to Earnings and Growth Ratio|Trevi Therapeutics Inc - PEG Multiple|Growth-Adjusted Payback Ratio PRAX (Praxis Precision Medicines)|AVXL: PEG Multiple|CBLL - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio prothena.com|Price/Earnings to Growth Multiple Alector (ALEC)|Price/Earnings to Growth Multiple ANNX (annexonbio.com)|OMER - Price to Earnings Adjusted for Growth Rate|PEG Multiple NGNE (Neurogene Inc)|PEG Multiple AC Immune S.A. ACIU|VYGR - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio NMRA|SCLX (Scilex Holding Company) - Price/Earnings to Growth Multiple|TVGN (Tevogen Bio Holdings) - Price/Earnings to Growth Ratio|ACOG (Alpha Cognition Corp) - PEG Multiple|Cognition Therapeutics, Inc. - Market Cap to Earnings and Growth Ratio|PEG Multiple IKT|SAVA (Cassava) - Growth-Adjusted Payback Ratio|Assertio Holdings, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio COYA|VistaGen Therapeutics, Inc. - PEG Multiple|Growth-Adjusted Market Cap to Net Income Ovid Therapeutics OVID|ABOS: PEG Multiple|CervoMed Corporation (CRVO) - PEG Multiple|Price/Earnings to Growth Ratio Alterity Therapeutics Limited|Price/Earnings to Growth Ratio CLNN|PEG Multiple PEPG|JUNS (Jupiter Neurosciences) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Relmada Corp RLMD|PEG Multiple Annovis Bio Corporation ANVS|gracetx.com - PEG Multiple|Firefly Neuroscience, Inc (AIFF) - Price/Earnings to Growth Multiple|Klotho Neurosciences (KLTO) - Price/Earnings to Growth Ratio|NeuroSense Therapeutics, Ltd. - Growth-Adjusted Payback Ratio|RVPH (Reviva Pharmaceuticals Holdings) - PEG Multiple|MetaVia Inc (MTVA) - Growth-Adjusted Market Cap to Net Income|PEG Multiple NRXS|Growth-Adjusted Market Cap to Net Income Helius Medical Technologies Inc.|Price/Earnings to Growth Ratio passagebio.com PASG|NEUP: Growth-Adjusted P/E Ratio|NERV - Price/Earnings to Growth Ratio|Athira - Company Value to Earnings Growth Ratio|ADXN: PEG Multiple|ALZN (Alzamend Neuro, Inc.) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Ratio protagenic.com|Pasithea Therapeutics - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Multiple CRGT (Cortigent, Inc.)|Avenue Therapeutics - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Brainstorm Cell BCLI|PEG Multiple caratherapeutics.com CARA|Chromocell Therapeutics Corp. - PEG Multiple|eliemtx.com - Company Value to Earnings Growth Ratio|Intra-Cellular Therapies (ITCI) - Price/Earnings to Growth Ratio|LBPH (Longboard) - Price/Earnings to Growth Ratio|MRNS (marinuspharma.com) - PEG Multiple|Price to Earnings Adjusted for Growth Rate NKGen Biotech NKGN|Price/Earnings to Growth Ratio NeuroBo Pharma (NRBO)|Company Value to Earnings Growth Ratio SAGE|Synaptogenix, Inc. - Price/Earnings to Growth Multiple|TRVN: Growth-Adjusted P/E Ratio|VIGL - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio WENA (Anew Medical, Inc.)|CERE: PEG Multiple